asco lc highlights, pt 6: benefit of chemotherapy vs. egfr inhibitor therapy in second line
Published 10 years ago • 87 plays • Length 6:38Download video MP4
Download video MP3
Similar videos
-
5:20
asco lung cancer highlights, pt 11: nintedanib with second line chemotherapy
-
7:39
chemotherapy and immunotherapy for patients with kras mutations - asco lung review 2022
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20
-
5:40
asco lung cancer highlights, pt 12: ganetespib with second line chemotherapy
-
8:49
grace targeted therapies lung cancer 2021 - a role for chemo io in patients with egfr mutations?
-
11:13
gracecast-091_lung-cancer_highlights 2011: the egfr axis
-
7:35
treatment for patients with egfr nsclc - leading developments & current questions in lung cancer
-
14:00
asco 2021 lung recap: impower010: atezolizumab after chemo in non-small cell lung cancer
-
16:03
grace targeted therapies lung cancer 2021 -the role of chemotherapy in driver positive patients
-
6:40:28
full video ondemand -targeted therapies patient forum 2022 - for those living with lung cancer
-
7:28
egfrm nsclc: should we treat with durvalumab? - asco lung review 2022
-
13:31
gracecast- asco lung 2020- the sindas trial - the addition of sbrt to a systemic egfr inhibitor tki
-
7:44
asco lung cancer highlights, part 1: introduction to stage iii nsclc
-
8:13
checkmate 816: combining chemo and opdivo - asco lung review 2022
-
9:49
asco lung cancer highlights, pt 9: the madeit study of predictive biomarkers for chemotherapy
-
7:22
debating egfr inhibitors for squamous cell lung cancer patients
-
22:49
grace targeted therapies lung cancer 2021 - management of uncommon egfr mutations including exon 20
-
16:39
gracecast-067_lung-cancer_expert round table - nsclc molecular markers case 3
-
7:48
should avastin be added to egfr tki therapy for egfr mutation-positive nsclc?